Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Assets Average (2016 - 2025)

Historic Assets Average for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Assets Average fell 2091.01% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 2091.01%. This contributed to the annual value of $1.5 billion for FY2024, which is 138.28% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Assets Average stood at $1.2 billion, which was down 2091.01% from $1.3 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Assets Average high stood at $1.7 billion for Q1 2021, and its period low was $1.2 billion during Q3 2025.
  • Its 5-year average for Assets Average is $1.4 billion, with a median of $1.5 billion in 2024.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 4174.06% in 2021, then plummeted by 2091.01% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Assets Average (Quarter) stood at $1.5 billion in 2021, then grew by 5.21% to $1.6 billion in 2022, then decreased by 13.74% to $1.4 billion in 2023, then increased by 11.46% to $1.5 billion in 2024, then decreased by 17.92% to $1.2 billion in 2025.
  • Its Assets Average stands at $1.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.4 billion for Q1 2025.